Clinical Trial Update: A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 randomized trial of Amplimexon (Imexon) with gemcitabine in pancreatic cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neoplasms

Drugs mentioned

• Amplimexon
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: AmpliMed Corporation | Conditions: Pancreatic Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2010-11-30